View More Recent Stories
-
EF Hutton Starts NRx Pharmaceuticals, Inc. (NRXP) at Buy
-
NRx Pharmaceuticals (NRXP) and HOPE Therapeutics to Acquire a Premier West Coast Interventional Psychiatric Clinic
-
NRx Pharmaceuticals (NRXP) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100
-
HOPE Therapeutics and NRx Pharmaceuticals (NRXP) Announce Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics
-
NRx Pharmaceuticals (NRXP) Announces CEO Resignation
-
NRx Pharmaceuticals (NRXP) Announces Up to $16M Secured Debt Financing from Anson Funds
-
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NRXP) Announce Alignment with FDA on Pediatric Study Plan for NRX-100
-
HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NRXP) Announce Arbitration Order Enabling HOPE Therapeutics Spinoff
-
NRx Pharmaceuticals (NRXP) Issues Shareholder Letter
-
NRx Pharmaceuticals (NRXP) to Proceed with Two New Drug Applications in 2024, NRX-101 Returned to the Company for Filing
-
NRx Pharmaceuticals (NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors
-
NRx Pharmaceuticals (NRXP) Issues Shareholder Update Letter

